Graybug Announces Name and Trading Symbol Change
March 20 2023 - 1:22PM
Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) today announced that
it has changed its name to CalciMedica, Inc. (the Company), which
will become effective at 4:02 pm ET. In connection with the name
change, the Company has changed its trading symbol to “CALC.” The
Company’s common stock will commence trading on March 21, 2023 on
the Nasdaq Global Market under the trading symbol “CALC.” The name
and trading symbol change were undertaken in connection with the
previously announced merger between Graybug and CalciMedica, Inc.
(CalciMedica).
About GraybugGraybug is a
clinical-stage biopharmaceutical company focused on developing
transformative medicines for ocular diseases. Founded in 2011 based
on technology licensed from the Johns Hopkins University School of
Medicine, Graybug has offices in Redwood City, CA, and Baltimore,
MD. For more information, please visit www.graybug.vision.
About CalciMedicaCalciMedica is
a clinical-stage biopharmaceutical company focused on developing
therapies for life-threatening inflammatory diseases with high
unmet need. CalciMedica’s proprietary technology targets the
inhibition of calcium release-activated calcium (CRAC) channels
designed to modulate the immune response and protect against tissue
cell injury, with the potential to provide therapeutic benefits in
life-threatening inflammatory diseases for which there are
currently no approved therapies. CalciMedica’s lead product
candidate Auxora, a proprietary, intravenous-formulated CRAC
channel inhibitor, has demonstrated positive and consistent
clinical results in four completed efficacy clinical trials. Auxora
is in development for acute pancreatitis and
asparaginase-associated pancreatitis. CalciMedica was founded by
scientists from Torrey Pines Therapeutics and the Harvard CBR
Institute for Biomedical Research, and is headquartered in La
Jolla, CA. For more information, please visit
www.calcimedica.com.
Forward-Looking
Statements This
press release contains forward-looking statements which include,
but are not limited to, statements regarding expected timing of the
effectiveness of the Company’s name and symbol change. These
forward-looking statements are subject to the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995. The Company’s expectations and beliefs regarding these
matters may not materialize. Actual outcomes and results may differ
materially from those contemplated by these forward-looking
statements as a result of uncertainties, risks, and changes in
circumstances, including but not limited to risks and uncertainties
related to those contemplated by the forward-looking statements are
included under the caption “Risk Factors” and elsewhere in the
Company’s most recent filings with the Securities and Exchange
Commission (SEC), including its definitive proxy statement filed
with the SEC on February 9, 2023 and its Annual Report on Form 10-K
for the quarter ended December 31, 2022 and any subsequent reports
on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to
time and available at www.sec.gov. These documents can be accessed
on Graybug’s web page at https://investors.graybug.vision/ by
clicking on the link “Financials and Filings.”
Graybug Contacts: |
|
|
|
Investor Contact |
Media Contact |
IR@graybug.vision |
media@graybug.vision |
(650) 487-2409 |
(404) 384-0067 |
|
|
CalciMedica Contacts: |
|
|
|
Investors and Media |
|
Argot Partners |
|
Sarah Sutton/Kevin Murphy |
|
calcimedica@argotpartners.com |
(212) 600-1902 |
|
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jul 2023 to Jul 2024